Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc. is focused on innovative antiviral therapies targeting diseases linked to virus-triggered immune responses, including fibromyalgia and long COVID. The company’s recent licensing agreement with Serpin Pharma for the global rights to SP16 may present significant revenue opportunities, indicating strong potential for growth in the biotechnology sector. Additionally, the anticipated initiation of the SP16 clinical program and an increase in the company’s projected revenue streams contribute to a positive financial outlook for Dogwood Therapeutics.

Bears say

Dogwood Therapeutics Inc, a development-stage biotechnology company, is focused on advancing novel antiviral therapies but faces challenges in generating significant revenue due to its early-stage product candidates, IMC-1 and IMC-2. Despite a reported low dropout rate of 4.4%, suggesting potential patient satisfaction, the company remains reliant on the successful progression of its clinical trials and regulatory approvals, which are inherently risky and uncertain. Additionally, the lack of established partnerships, funding pressures, and the competitive landscape within the biotechnology sector further contribute to a negative outlook on the company's stock performance.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.